Table 1.
The characteristics of included studies.
| N0. | Study | Clinical Trials. gov number | Phase | Study design | Number of patients | Disease | Ages(years), medium(range) | Treatment | Prior lines of therapy | Any grade AEs (n) | grade ≥3 AEs (n) | CR (%) | PR (%) | ORR (%) | SDR (%) | DCR (%) | PDR (%) | Median PFS (m) | Median OS (m) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Liu et al., 2022 (27) | NCT03498430 | I | single-arm | 13 | R/R indolent B-NHL | 40 (30–64) | copanlisib | 1-8 | 13 | 10 | 0 | 58.3% | 58.30% | 41.6% | 100% | 0 | — | — |
| 2 | Lenz et al., 2020 (28) | NCT02391116 | II | single-arm | 67 | R/R aggressive B-NHL | 69(25–93) | copanlisib | 1-13 | 65 | 58 | 7.5% | 11.9% | 19.40% | 20.9% | 40.30% | 44.80% | 1.8 | 7.4 |
| 3 | Dreyling et al., 2017 (1) (29) | NCT01660451 -part A | II | single-arm | 33 | R/R indolent B-NHL | 66.5 (22–90) | copanlisib | 1-10 | 33 | 6.3% | 34.4% | 43.80% | 45.5% | 90.60% | 3% | 9.8 | 21.9 | |
| Dreyling et al., 2017 (2) (29) | 34 | R/R aggressive B-NHL | — | — | 0 | 23.5% | 29.40% | 17.6% | 47.10% | 32.40% | — | — | |||||||
| 4 | Dreyling et al., 2020 (23) | NCT01660451 -part B | II | single-arm | 142 | R/R indolent B-NHL | 63 (25–82) | copanlisib | 2-9 | 140 | 118 | 16.9% | 43.7% | 60.60% | 28.9% | 89.40% | 2.10% | 12.5 | 42.6 |
| 5 | Patnaik et al., 2016 (30) | NCT00962611 | I | dose-escalation | 9 | R/R B-NHL | 72 (40–84) | copanlisib | 1-8 | 8 | 6 | 11.1% | 66.7% | 77.80% | 0 | 77.80% | 22.20% | — | — |
| 6 | Morschhauser et al., 2020 (31) | NCT02155582 | I | single-arm | 26 | R/R aggressive B-NHL | 61 (38–80) | copanlisib | — | — | — | 3.8% | 19.2% | 23.10% | — | — | — | — | — |
| 7 | Matasar et al., 2021a (24) | NCT02367040 | III | double-blind, randomised | 307 | R/R indolent B-NHL | 63 (54–70) | copanlisib+rituximab | — | 293 | 280 | 33.9% | 44.6% | 81% | 11.7% | 89% | 2% | 21.5 | — |
| 8 | Matasar et al., 2021b (1) (32) | NCT02626455 | III | double-blind, randomised | 10 | R/R indolent B-NHL | 62 (41-82) | copanlisib++R-B | 1-3 | 10 | 7 | 50% | 40% | 90% | 10% | 100% | 0 | — | — |
| Matasar et al., 2021b (2) (32) | 11 | R/R indolent B-NHL | 64 (46-78) | copanlisib++R-CHOP | 11 | 10 | 30% | 70% | 100% | 0 | 100% | 0 | — | — |
R/R, relapsed or refractory; B-NHL, B-cell non-Hodgkin lymphoma; R-B, rituximab + bendamustine; R-CHOP, rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone.